| HOME >> BIOLOGY >> TECHNOLOGY |
Gross margin 50% 55%
Operating expenses:
Research and development 60,733 (10,693)(b)(c)(d) 50,040
Selling, general and
administrative 307,479 (85,121)(b)(c)(d) 222,358
Total operating expenses 368,212 (95,814) 272,398
Operating income (loss) 18,280 136,653 154,933
Interest and other income
(expense), net (59,399) 8,315 (c)(g) (51,084)
Income tax (benefit)
provision (8,578) 45,032 (i) 36,454
Equity earnings of
unconsolidated entities,
net of tax (1,981) 6,441 (b)(c) 4,460
Net (loss) income $(34,522) $106,377 $71,855
Preferred stock dividends $(3,107) $(3,107)
Net (loss) income available
to common stockholders -
basic $(37,629) $68,748
Net (loss) income per common
share
Basic $(0.49) $0.89
Diluted $(0.49)(j) $0.84 (k)
Weighted average common shares
- basic 77,446 77,446
Weighted average common shares
- diluted 77,446 (j) 83,201 (k)
Six Months Ended June 30, 2007
Non-GAAP
Adjusted
Non-GAAP Cash
GAAP Adjustments Basis (a)
Net revenue $313,944 $-
'/>"/>
| SOURCE Inverness Medical Innovations, Inc. Copyright©2008 PR Newswire. All rights reserved |